Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) closed a public offering on March 25, 2026, selling 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares at a combined public offering price of $0.25 per share and warrant.
The offering generated aggregate gross proceeds of $5.0 million before fees; the warrants have a $0.25 exercise price, are exercisable immediately and expire five years from issuance. The company intends to use net proceeds primarily for working capital and general corporate purposes.
Positive
- Raised $5.0 million gross proceeds from common shares and warrants
- Warrants provide potential additional cash of $5.0 million if fully exercised
- Net proceeds earmarked for working capital and general corporate purposes
Negative
- Issued 20,000,000 new common shares, creating immediate dilution
- Up to 20,000,000 warrants exercisable at $0.25 create potential future dilution
- Shares and warrants sold at a combined price of $0.25, indicating low per-share raise
News Market Reaction – OTLK
In the Mar 26 session, OTLK gained 0.96%, reflecting a mild positive market reaction. Argus tracked a peak move of +10.5% during that session. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Offering priced | Negative | -38.1% | Pricing of $5.0M equity-plus-warrants financing at $0.25 per unit. |
| Mar 23 | Offering proposed | Negative | -38.1% | Announcement of best-efforts public offering for stock and warrants. |
| May 23 | Offering priced | Negative | -2.4% | Pricing of $13.0M public offering with share-and-warrant structure. |
| May 22 | Offering proposed | Negative | -2.4% | Proposed public offering of common stock and warrants for funding. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related announcements have consistently triggered negative reactions, with an average move of -20.25% across four recent financings.
Recent activity centers on serial equity offerings. On May 22–23, 2025, proposed and priced offerings led to share and warrant issuance with 24-hour moves of about -2.44%. In March 2026, the company again filed proposed and then priced a $5.0 million public offering, each linked to a -38.06% move. Today’s closing of the same $5.0 million deal follows this established financing pattern and adds execution confirmation rather than new terms.
Key Terms
warrants financial
public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of
The aggregate gross proceeds of the offering were
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The securities described above were offered by Outlook Therapeutics pursuant to a “shelf” registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024, and became effective on April 5, 2024. The public offering was made only by means of a prospectus supplement and an accompanying prospectus that form a part of the effective registration statement. A final prospectus supplement and an accompanying prospectus has been filed with the SEC and is available for free on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711, or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Forward-Looking Statements
This press release contains statements that may or are considered “forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include statements regarding, among others, the expected use of proceeds from the public offering, the potential receipt of additional gross proceeds on exercise of the common warrants, as well as the potential of ONS-5010/LYTENAVA™ as a treatment for retina diseases, the potential for ONS-5010 to receive approval from the FDA, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as supplemented by subsequent reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the global geopolitical conflict, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
